Author's Reply: Neutrophil‐Macrophage Interactions in Gastric Cancer Authors: Keita H Nagaoka, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Takuya Nakatsuru, Ryo Kamata, Shunsuke A Sakai, Gaku Yamamoto, Tomoko Y Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Sai M Pulukuri, Yuko Ishii, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi Published: 2026 Dear Editor, We read with great interest the recent letter regarding our published study on the critical role of neutrophil‐macrophage interactions in reshaping the gastric cancer tumor microenvironment during chemoimmunotherapy [1]. We sincerely appreciate these thoughtful, constructive, and highly sophisticated methodological considerations, which provide valuable avenues for further expanding the translational impact of our findings. The letter elegantly highlights the opportunities presented by our cohort size (n=18) and cross‐sectional sampling design. We completely agree that larger, prospectively collected, and paired pre and posttreatment cohorts represent the gold standard for clinical translation, as we noted in our original publication [1]. Given the inherent practical challenges of acquiring sequential drug‐exposed clinical biopsies, we designed our study to generate a high‐resolution, hypothesis‐generating dataset. To robustly complement this clinical cohort, we utilized a well‐controlled in vivo syngeneic murine model [1]. This dual approach successfully demonstrated that neutrophil depletion alters the antitumor efficacy of chemo‐immunotherapy and selectively modulates macrophage infiltration [1], thereby supporting the biological relevance of our single‐cell observations. We look forward to future multi‐center prospective studies that will naturally build upon these foundational insights. Regarding the recommendation for spatial or in situ validation of the neutrophil‐macrophage physical proximity, we fully concur with this excellent perspective. Incorporating spatial transcriptomics or multiplexed immunohistofluorescence is indeed a powerful next step to visually map these cellular neighborhoods. While our current work relied on in silico cell–cell communication modeling, we proactively highlighted the lack of spatial resolution as an important area for future investigation [1]. We believe that coupling our functional in vivo data with future spatial validation will further refine our understanding of the tumor microenvironment's spatial architecture. We also appreciate the focus on the technical aspects of capturing low‐RNA‐content neutrophils and ensuring lineage purity. This is indeed a critical quality control consideration in single‐cell transcriptomics. To address potential monocyte or macrophage contamination, our pipeline strictly evaluated key lineage‐specific markers across all neutrophil clusters [1]. In our published supplemental data, canonical macrophage and monocyte markers (including CD14, FCN1, and C1Q family genes) were minimally expressed or absent in our neutrophil subclusters, including the HLA‐DRA + Neut4 population, while neutrophil‐specific markers (S100A8, S100A9) remained robustly high [1]. This distinct segregation on a per‐cell basis supports the high purity and fidelity of our annotated neutrophil subsets. Finally, the suggestion to target specific ligand‐receptor axes, such as the CCL/CCR or MIF‐CD74 pathways, is highly sophisticated and scientifically exciting. While our current in vivo depletion studies established the overall functional necessity of neutrophils [1], directly blocking these specific signaling axes represents the logical next phase of our research. We have extensively discussed these pathways as promising therapeutic strategies in our article [1], and we are actively planning to explore these precise targetings in our upcoming studies. In conclusion, we are deeply grateful for these stimulating comments. This constructive scientific dialogue significantly enriches the discussion surrounding our work and helps pave the way for future breakthroughs in understanding the gastric cancer microenvironment. Author Contributions Keita H. Nagaoka: conceptualization, methodology, data curation, formal analysis, validation, investigation, writing – original draft. Hiroki Yamashita: methodology, investigation, formal analysis. Chiaki Mashima: investigation, methodology, formal analysis. Guoqiang Zhang: investigation, methodology, formal analysis. Hitoshi Saito: methodology, data curation, formal analysis, investigation. Tatsunori Minamide: methodology, formal analysis, investigation. Takuya Nakatsuru: methodology, investigation, data curation, validation. Ryo Kamata: investigation, validation, formal analysis. Shunsuke A. Sakai: investigation, methodology. Gaku Yamamoto: investigation, methodology. Tomoko Y. Morita: investigation, methodology. Kazuki Nakai: investigation, methodology. Yumi Hakozaki: investigation, methodology. Kumi Kinoshita: investigation, methodology. Yui Takahashi: investigation, methodology. Izuma Nakayama: investigation, resources. Akihito Kawazoe: investigation, resources. Sai M. Pulukuri: investigation, resources. Yuko Ishii: investigation, conceptualization, formal analysis. Hiroshi Haeno: investigation, methodology, supervision, writing – review and editing. Yukie Kashima: investigation, methodology, supervision, writing – review and editing. Kohei Shitara: investigation, resources, supervision, writing – review and editing. Tomonori Yano: investigation, supervision, writing – review and editing. Takeshi Saito: conceptualization, investigation, supervision, writing – review and editing. Akihiro Ohashi: conceptualization, supervision, writing – review and editing, funding acquisition, investigation. Funding This research was supported by Astellas Pharma Global Development Inc. This research was also supported by Grants‐in‐Aid for Scientific Research (B) (25K02540 and 20H03541), Grants‐in‐Aid for Fostering Joint International Research (B) (20KK0187), and the Takeda Science Foundation (2019, 2022). Supercomputing resources were provided by the Human Genome Center (University of Tokyo). Ethics Statement Research protocol approval by an institutional reviewer: This study was approved by our institutional review board (registration number 2021‐019) and performed in accordance with the ethical principles outlined in the Declaration of Helsinki. Informed Consent: All participants gave written informed consent for study participation. Registry and Registration No. of the study/trial: N/A. Animal studies: The protocol and any amendments or procedures involving the care and use of animals in this study were reviewed and approved by the National Cancer Center of Japan (approval number: K24014) before initiation of the study. Animal care and use were conducted in accordance with the regulations of the AAALAC. Consent All participants gave written informed consent for study participation. Conflicts of Interest K.H.N. and T.N. are employees of Astellas Pharma Inc. G.Z., Q.X., Y.I., and T.S. are employees of Astellas Pharma Global Development Inc. I.N. received research funding from Astellas, Ono Pharmaceutical Co. Ltd., Merck Sharp & Dohme (MSD), Daiichi Sankyo, Boehringer Ingelheim, and Chugai Pharmaceutical Co. Ltd., and honoraria from Astellas, Ono Pharmaceutical Co. Ltd., Bristol Myers Squibb (BMS), MSD, Daiichi Sankyo, and Chugai Pharmaceutical Co. Ltd. A.K. reports grants from AstraZeneca, SHIONOGI, and AbbVie; consulting fees or an advisory board from Zymeworks, MSD, GSK, and AbbVie; and honoraria from Taiho Pharmaceutical, Bristol Myers Squibb, Merck Serono, Ono, Daiichi Sankyo, Takeda Pharmaceutical, and Guardant Health. K.S. reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology Inc., Bayer, GlaxoSmithKline K.K., HEALIOS K.K., Moderna Inc., and Arcus Biosciences Inc.; receiving honoraria from Bristol‐Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas, and AstraZeneca; and receiving research funding (all to our institution) from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Amgen, Eisai, PRA Health Sciences, Syneos Health, AstraZeneca, PPD‐SNBL K.K., and TORAY. A.O. is a part‐time employee of Astellas Pharma Inc. under a cross‐appointment system (2022–present). A.O. was previously an employee of Takeda Pharmaceutical Company Ltd. (2006–2018). A.O. reports paid consulting and advisory roles for Ono Pharmaceutical Company Ltd., Craif Inc., and GEXVal Inc. A.O. received research funding from Takeda Pharmaceutical Company, Daiichi‐Sankyo, and Astellas Pharma. H.Y., C.M., H.S., T.M., R.K., S.A.S., G.Y., T.M., K.N., Y.H., Y.H., K K., Y.T., H.H., Y.K., and T.Y. declare no competing interests. Linked Articles Neutrophil‐Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer during Chemo‐Immunotherapy. To view this article, visit https://doi.org/10.1111/cas.70384. Acknowledgments We are grateful to the members of the Aki Ohashi Laboratory. We thank Qunli Xu for assistance with the initial study design. We acknowledge Tohru Kiyono, Riu Yamashita, and Katsuya Tsuchihara for their valuable comments regarding the manuscript and for their technical support. We also thank Taku Yoshida, Ryuichi Moriya, Kenna Shirasuna, and Shinsuke Oshima for their support. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Reference Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.